Press Release Archive
-
Janssen Reports Positive Topline Results for ATLAS Phase III Study of a Novel, Long Acting Injectable Two-Drug Regimen for the treatment of HIV-1Janssen Reports Positive Topline Results for ATLAS Phase III Study of a Novel, Long Acting Injectable Two-Drug Regimen for the treatment of HIV-1
-
Johnson & Johnson Announces Chris DelOrefice as Vice President of Investor RelationsJohnson & Johnson Announces Chris DelOrefice as Vice President of Investor Relations
-
Janssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX® (daratumumab) Split Dosing RegimenJanssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX® (daratumumab) Split Dosing Regimen
-
Johnson & Johnson to Participate in Barclays Global Consumer Staples ConferenceJohnson & Johnson to Participate in Barclays Global Consumer Staples Conference
-
Johnson & Johnson to Participate in the 2018 Wells Fargo 13th Annual Healthcare ConferenceJohnson & Johnson to Participate in the 2018 Wells Fargo 13th Annual Healthcare Conference
-
Johnson & Johnson Announces Series of Collaborations Aimed at Transforming Mental Health Care in Low-Resource SettingsJohnson & Johnson Announces Series of Collaborations Aimed at Transforming Mental Health Care in Low-Resource Settings
-
Johnson & Johnson Consumer Inc. Announces Agreement to Acquire Zarbee’s, Inc., a Leader in Naturally-Based Healthcare ProductsJohnson & Johnson Consumer Inc. Announces Agreement to Acquire Zarbee’s, Inc., a Leader in Naturally-Based Healthcare Products
-
FIRST ISCHEMIC STROKE PATIENTS TREATED WITH EMBOTRAP II REVASCULARIZATION DEVICE SINCE COMMERCIAL AVAILABILITY IN U.S.FIRST ISCHEMIC STROKE PATIENTS TREATED WITH EMBOTRAP II REVASCULARIZATION DEVICE SINCE COMMERCIAL AVAILABILITY IN U.S.
-
Janssen announces JULUCA® (dolutegravir/rilpivirine) maintains viral suppression with two drugs in a once-daily, single-pillJanssen announces JULUCA® (dolutegravir/rilpivirine) maintains viral suppression with two drugs in a once-daily, single-pill
-
Janssen Presents Switch Data for New HIV-1 Treatment SYMTUZA™ (D/C/F/TAF) and Second Study Supporting its Use in a Rapid Initiation ScenarioJanssen Presents Switch Data for New HIV-1 Treatment SYMTUZA™ (D/C/F/TAF) and Second Study Supporting its Use in a Rapid Initiation Scenario